Effect of telavancin on human intestinal microflora

International Journal of Antimicrobial Agents

Volumn 38, Issue 6, 2011, Pages 474-479

  Rashid, Mamun Ur ^a   Weintraub, Andrej ^a   Nord, Carl Erik ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Ecological impact; Human intestinal microflora; Telavancin

Indexed keywords

TELAVANCIN;

ABNORMAL URINE COMPOSITION; ADULT; AEROBIC BACTERIUM; ANAEROBIC BACTERIUM; AREA UNDER THE CURVE; ARTICLE; BACTERIAL COUNT; BACTERIUM CULTURE; BACTEROIDES; BIFIDOBACTERIUM; BLOOD ANALYSIS; CANDIDA ALBICANS; CLOSTRIDIA; CLOSTRIDIUM DIFFICILE; CONTINUOUS INFUSION; CULTURE MEDIUM; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG EXCRETION; DRUG FATALITY; DRUG FECES LEVEL; DRUG HALF LIFE; DRUG URINE LEVEL; ENTEROBACTERIACEAE; ENTEROCOCCUS; FECES ANALYSIS; FEMALE; GASTROINTESTINAL DISEASE; GRAM POSITIVE BACTERIUM; HEADACHE; HUMAN; HUMAN EXPERIMENT; INTESTINE FLORA; LACTOBACILLUS; MALE; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; NAUSEA; NORMAL HUMAN; PATIENT COMPLIANCE; PRIORITY JOURNAL; SINGLE DRUG DOSE; SOMNOLENCE; TASTE DISORDER; URINALYSIS; VOLUNTEER;

ADOLESCENT; ADULT; AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; BACTERIA; DRUG RESISTANCE, BACTERIAL; ECOSYSTEM; FECES; FEMALE; HUMANS; INTESTINES; MALE; MICROBIAL SENSITIVITY TESTS; YOUNG ADULT;

EID: 80255124878     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2011.08.012     Document Type: Article

References (23)

1. . Sullivan, C. Edlund, and C.E. Nord Interaction between antimicrobial agents and the oropharyngeal and the intestinal microflora A. Bryskier, Antimicrobial agents 2005 ASM Press Washington, DC 1357 1370
2. European Agency for the Evaluation of Medicinal Products. Points to consider on pharmacokinetics and pharmacodynamics in the development of antibacterial medicinal products. London, UK: EMEA; 2000. CPMP/EWP/2655/99.
3. . Sullivan, C. Edlund, and C.E. Nord Effect of antimicrobial agents on the ecological balance of human microflora Lancet Infect Dis 1 2001 101 114 (Pubitemid 33586045)
4. D.L. Higgins, R. Chang, D.V. Debabov, J. Leung, T. Wu, and K.M. Krause Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus Antimicrob Agents Chemother 49 2005 1127 1134 (Pubitemid 40327734)
5. C.S. Lunde, S.R. Hartouni, J.W. Janc, M. Mammen, P.P. Humphrey, and B.M. Benton Telavancin disrupts the functional integrity of the bacterial membrane through targeted interaction with the cell wall precursor lipid II Antimicrob Agents Chemother 53 2009 3375 3383
6. L.D. Saravolatz, G.E. Stein, and L.B. Johnson Telavancin: a novel lipoglycopeptide Clin Infect Dis 49 2009 1908 1914
7. M.E. Stryjewski, D.R. Graham, S.E. Wilson, W. O'Riordan, D. Young, and A. Lentnek Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by Gram-positive organisms Clin Infect Dis 46 2008 1683 1693 (Pubitemid 351706765)
8. E. Rubinstein, T. Lalani, G.R. Corey, Z.A. Kanafani, E.C. Nannini, and M.G. Rocha Telavancin versus vancomycin for hospital-acquired pneumonia due to Gram-positive pathogens Clin Infect Dis 52 2011 31 40
9. T. Backstrom, G. Panagiotidis, O. Beck, C. Asker-Hagelberg, M.U. Rashid, and A. Weintraub Effect of ceftobiprole on the normal human intestinal microflora Int J Antimicrob Agents 36 2010 537 541
10. C.E. Nord, G. Rasmanis, and E. Wahlund Effect of dalbavancin on the normal intestinal microflora J Antimicrob Chemother 58 2006 627 631 (Pubitemid 44288129)
11. P.R. Murray, E.J. Baron, J.H. Jorgensen, M.L. Landry, and M.A. Pfaller Manual of clinical microbiology 9th ed. 2007 ASM Press Washington, DC
12. H. Huang, A. Weintraub, H. Fang, and C.E. Nord Comparison of a commercial multiplex real-time PCR to the cell cytotoxicity neutralization assay for diagnosis of Clostridium difficile infections J Clin Microbiol 47 2009 3729 3731
13. Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard. 7th ed. Document M7-A7. Wayne, PA: CLSI; 2006.
14. Clinical and Laboratory Standards Institute. Methods for antimicrobial susceptibility testing of anaerobic bacteria; approved standard. 7th ed. Document M11-A7. Wayne, PA: CLSI; 2007.
15. D.C. Draghi, B.M. Benton, K.M. Krause, C. Thornsberry, C. Pillar, and D.F. Sahm In vitro activity of telavancin against recent Gram-positive clinical isolates: results of the 2004-05 Prospective European Surveillance Initiative J Antimicrob Chemother 62 2008 116 121 (Pubitemid 351865882)
16. S.M. Finegold, M. Bolanos, P.H. Summanen, and D.R. Molitoris In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates Antimicrob Agents Chemother 53 2009 3996 4001
17. R.E. Mendes, G.J. Moet, M.J. Janechek, and R.N. Jones In vitro activity of telavancin against a contemporary worldwide collection of Staphylococcus aureus isolates Antimicrob Agents Chemother 54 2010 2704 2706
18. J.P. Shaw, J. Seroogy, K. Kaniga, D.L. Higgins, M. Kitt, and S. Barriere Pharmacokinetics, serum inhibitory and bactericidal activity, and safety of telavancin in healthy subjects Antimicrob Agents Chemother 49 2005 195 201 (Pubitemid 40065793)
19. 14C]telavancin following intravenous administration to healthy male volunteers Antimicrob Agents Chemother 54 2010 3365 3371
20. S.L. Wong, S.L. Barriere, M.M. Kitt, and M.R. Goldberg Multiple-dose pharmacokinetics of intravenous telavancin in healthy male and female subjects J Antimicrob Chemother 62 2008 780 783
21. G.G. Zhanel, D. Calic, F. Schweizer, S. Zelenitsky, H. Adam, and P.R. Lagace-Wiens New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin Drugs 70 2010 859 886 [Erratum in: Drugs 2001;71:526]
22. P.C. Appelbaum, and P.A. Hunter The fluoroquinolone antibacterials: past, present and future perspectives Int J Antimicrob Agents 16 2000 5 15 (Pubitemid 30665419)
23. R.C. Spencer The role of antimicrobial agents in the aetiology of Clostridium difficile-associated disease J Antimicrob Chemother 41 Suppl. C 1998 21 27 (Pubitemid 28230296)